| 常英英,张海丽,赵 双,刘新正,郭克锋.射频消融联合帕博利珠单抗对肝细胞癌的应用效果及肿瘤标志物、CAC1、CCNB2水平影响[J].,2024,(20):3935-3937 |
| 射频消融联合帕博利珠单抗对肝细胞癌的应用效果及肿瘤标志物、CAC1、CCNB2水平影响 |
| The Application Effect of Radiofrequency Ablation Combined with Pembrolizumab on Hepatocellular Carcinoma and the Influence ofTumor Markers, CAC1, and CCNB2 Levels |
| 投稿时间：2024-03-14 修订日期：2024-04-06 |
| DOI：10.13241/j.cnki.pmb.2024.20.036 |
| 中文关键词: 射频消融 帕博利珠单抗 肝细胞癌 肿瘤标志物 |
| 英文关键词: Radiofrequency ablation Pabolizumab Hepatocellular carcinoma Tumor markers |
| 基金项目:河南省医学科技攻关计划项目（LHGJ20221041） |
|
| 摘要点击次数: 20 |
| 全文下载次数: 18 |
| 中文摘要: |
| 摘要 目的：探讨射频消融联合帕博利珠单抗对肝细胞癌的应用效果及肿瘤标志物、CAC1、CCNB2水平影响。方法：选取我院2020.1到2023.1收治的60例肝细胞癌患者，分为观察组与对照组，各30例。对照组采取射频消融治疗，术后采取常规化疗，观察组在对照组基础上采取帕博利珠单抗治疗。对比两组相关指标。结果：观察组ORR与DCR明显高于对照组（P＜0.05）；治疗后观察组肿瘤标志物水平均低于对照组（P＜0.05）；治疗后观察组患者CAC1、CCNB2阳性率均低于对照组（P＜0.05）；两组患者不良反应发生率对比无差异（P＞0.05）。结论：射频消融联合帕博利珠单抗治疗肝细胞癌疗效显著，可提升其客观缓解率与疾病控制率，降低肿瘤标志物水平，其疗效优异性可能与对CAC1、CCNB2调节作用相关，且联合治疗安全性较高。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of radiofrequency ablation combined with pabolizumab on hepatocellular carcinoma (HCC) and the effects of tumor markers, CAC1 and CCNB2 levels. Methods: Selected from 2020.1 to 2023.1 were 60 cases of patients with hepatocellular carcinoma (HCC), divided into observation group and control group, 30 cases each. The control group was treated with radiofrequency ablation and conventional chemotherapy after operation. The observation group was treated with pabolizumab on the basis of the control group. Compare the two groups of relevant indicators. Results: ORR and DCR in observation group were significantly higher than those in control group (P<0.05). Level of tumor markers in observation group were lower than the control group after treatment (P<0.05); After treatment, the positive rates of CAC1 and CCNB2 in observation group were lower than those in control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Radiofrequency ablation combined with pembrolizumab is effective in the treatment of hepatocellular carcinoma, which can improve the objective response rate and disease control rate, and reduce the level of tumor markers. The excellent efficacy may be related to the regulation of CAC1 and CCNB2, and the combined treatment is safe. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
